Klaus H Shindhelm Net Worth

The estimated Net Worth of Klaus H Shindhelm is at least $961 Thousand dollars as of 11 August 2003. Klaus Shindhelm owns over 3,800 units of Resmed stock worth over $961,096 and over the last 21 years Klaus sold RMD stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Klaus Shindhelm RMD stock SEC Form 4 insiders trading

Klaus has made over 1 trades of the Resmed stock since 2003, according to the Form 4 filled with the SEC. Most recently Klaus exercised 3,800 units of RMD stock worth $42,978 on 11 August 2003.

The largest trade Klaus's ever made was exercising 3,800 units of Resmed stock on 11 August 2003 worth over $42,978. On average, Klaus trades about 1,900 units every 0 days since 2003. As of 11 August 2003 Klaus still owns at least 3,800 units of Resmed stock.

You can see the complete history of Klaus Shindhelm stock trades at the bottom of the page.

What's Klaus Shindhelm's mailing address?

Klaus's mailing address filed with the SEC is 10 WILLIAMSTOWN COURT, (AUSTRALIA), GLENHAVEN, C3, 2156.

Insiders trading at Resmed

Over the last 22 years, insiders at Resmed have traded over $250,830,262 worth of Resmed stock and bought 10,000 units worth $424,500 . The most active insiders traders include Peter C Farrell, Gary W Pace, and David Pendarvis. On average, Resmed executives and independent directors trade stock every 7 days with the average trade being worth of $3,005,701. The most recent stock trade was executed by Brett Sandercock on 9 September 2024, trading 1,000 units of RMD stock currently worth $246,420.

What does Resmed do?

at resmed (nyse: rmd, asx: rmd) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. our cloud-connected medical devices transform care for people with sleep apnea, copd and other chronic diseases. our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. by enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries.

Complete history of Klaus Shindhelm stock trades at Resmed

Resmed executives and stock owners

Resmed executives and other stock owners filed with the SEC include:

• Michael Farrell,
  Chief Executive Officer, Director
• Robert Douglas,
  President, Chief Operating Officer
• Jim Hollingshead,
  President – sleep and respiratory care business
• Rajwant Sodhi,
  President – Software as a Service Business (SaaS)
• Brett Sandercock,
  Chief Financial Officer
• Michael J. Farrell BE, SM, MBA,
  CEO & Director
• David Pendarvis,
  Chief Administrative Officer, Global General Counsel, Secretary
• Michael J. Farrell BE, MBA, SM,
  CEO & Director
• Robert A. Douglas,
  Pres & COO
• Dr. James R. Hollingshead Ph.D.,
  Pres of Sleep & Respiratory Care Bus.
• Brett A. Sandercock,
  Chief Financial Officer
• Peter Farrell,
  Non-Executive Chairman of the Board
• Dr. Peter C. Farrell A.M., AM, B.E., BE (Hons), Ph.D., ScD,
  Founder & Non-Exec. Chairman
• Dr. Peter C. Farrell A.M., B.E., Ph.D., BE (Hons), ScD, AM,
  Founder & Non-Exec. Chairman
• Ronald Taylor,
  Lead Independent Director
• Carol Burt,
  Independent Director
• Richard Sulpizio,
  Independent Director
• Harjit Gill,
  Independent Director
• Jan De Witte,
  Independent Director
• Karen Drexler,
  Independent Director
• Justin Leong,
  President – Asia and Latin America
• Urvashi Tyagi,
  Chief Technology Officer
• Nupur Bhushan,
  Chief People Officer
• David B. Pendarvis,
  Chief Admin. Officer, Global Gen. Counsel & Corp. Sec.
• Amy Wakeham,
  VP of Investor Relations & Corp. Communications
• Constance C. Bienfait,
  Director of Investor Relations
• Kaushik Ghoshal,
  Pres of SaaS Bus. & CTO
• John P Wareham,
  Director
• Christopher G Roberts,
  Director
• Donald Darkin,
  Sr. Vice President, Pat Inter
• Gary W Pace,
  Director
• Anne Reiser,
  President - ResMed Europe
• Richard Mc Hale,
  President, RC Business
• Inc Resmed,
  Director
• James Hollingshead,
  President, Sleep Business
• Kieran Gallahue,
  President, Global
• Paul Eisen,
  Vice President, Europe & Asia
• Donagh Mccarthy,
  Director
• Adrian M Smith,
  CFO
• Klaus H Shindhelm,
  Sr. Vice President, Operations
• Keith Serzen,
  Chief Operating Officer
• Louis A Simpson,
  Director
• Christopher Bartlett,
  Director
• Walter Flicker,
  VP and Asst. Corp. Secretary
• Lasse Beijer,
  COO-Europe
• Stein Jacobsen,
  COO, Europe
• Michael A Quinn,
  Director
• Kaushik Ghoshal,
  President, SaaS Business
• Lucile Blaise,
  President, Sleep & RC Business
• John Hernandez,
  Director
• Desney Tan,
  Director
• Michael J Rider,
  Global General Counsel
• Christopher Del Orefice,
  Director